Q/C Technologies, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Q/C Technologies, Inc. (QCLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 267.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 55.00K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 212.50K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 100.00K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was -222.75K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 102.25K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 129.84K shares, a 56.72% decline from fiscal 2022.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 300.00K shares.
- Q/C Technologies, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 38.50K shares, a 15.38% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 55.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 267.50K shares 10-Q · filed 2026-08-12 | 367.50K shares derived: sum of 3 quarters · filed 2026-08-12 | 144.75K shares derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | 212.50K shares 10-Q · filed 2026-05-15 | 312.50K shares derived: sum of 2 quarters · filed 2026-05-15 | 89.75K shares derived: sum of 3 quarters · filed 2026-05-15 | ||
| 2025-12-31 | 100.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -122.75K shares derived: sum of 2 quarters · filed 2026-04-15 | 102.25K shares 10-K · filed 2026-04-15 | ||
| 2025-09-30 | -222.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | 2.25K shares 10-Q · filed 2025-11-19 | |||
| 2025-06-30 | 225.00K shares 10-Q · filed 2025-08-19 | ||||
| 2023-12-31 | -3.72M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -2.62M shares derived: sum of 2 quarters · filed 2024-04-01 | 129.84K shares 10-K · filed 2024-04-01 | ||
| 2023-09-30 | 1.10M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 3.85M shares 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 2.75M shares 10-Q · filed 2023-08-14 | ||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-31 | 100.00K shares derived: sum of 3 quarters · filed 2023-03-31 | 300.00K shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 100.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 300.00K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 300.00K shares 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 200.00K shares 10-Q · filed 2022-05-16 | ||||
| 2016-12-31 | 38.50K shares 10-K/A · filed 2018-07-13 | ||||
| 2015-12-31 | 45.50K shares 10-K · filed 2017-04-11 | ||||
| 2015-12-30 | 15.50K shares 10-K · filed 2016-03-30 | ||||
| 2015-03-31 | 175.00K shares 10-Q · filed 2016-05-12 | 175.00K shares derived: sum of 2 quarters · filed 2016-05-12 | |||
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | 175.00K shares 10-K · filed 2016-03-30 | |||
| 2014-09-30 | 175.00K shares 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |